HER-2/neu over expression is associated with increased tumor aggressiveness, increased rates of recurrence, and increased mortality in node positive patien... MS Abdelhamid,SA Abdelaziz,SA Daoud,... - 《外科学(英文)》 被引量: 0发表: 2014年 Breast tumor recurrence following lumpectomy with and...
Breast cancer will be diagnosed in over 185,000 women in 1996 and will claim more than 44,000 lives (Parker et al, 1996). Antiestrogen (AE) therapy will widely be assigned to a large number of these individuals who are estrogen receptor-positive. Unfortunately, many of these women will ...
PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. Breast Cancer Res. 2009;11:R77. Article PubMed PubMed Central Google Scholar Finn RS, Crown JP, Lang I, Boer K, ...
Estrogen receptor (ER) and progesterone receptor (PR) testing are performed in the evaluation of breast cancer. While the clinical utility of ER as a predictive biomarker to identify patients likely to benefit from hormonal therapy is well-established, t
This new SERM also retains a similar positive effect in breast cancer prevention to raloxifene, with potentially improved cardiovascular benefits. Thus if lasofoxifene will be marketed at a similar cost to current products, its cost-effectiveness should be improved with respect to raloxifene. ...
3.17). The latter compound was approved in 2002 for the treatment of hormone-positive metastatic breast cancer.25,26 Sign in to download full-size image Fig. 3.17. Steroidal antiestrogens. As in the case of other antagonists, the binding of ICI-164384 or fulvestrant to the ER obstructs the...
Also, if a uterus is not present--and we're talking only about estrogen therapy, given its greater safety profile with long-term use with respect to breast cancer--clinicians and women can be more comfortable with continued use of low-dose systemic hormone therapy for osteoporosis prevention. ...
To show for the first time that the correlation between ESR1 expression and EERES is important for endocrine therapy responsiveness, we analyzed the survival of ER-positive/HER2-negative breast cancer patients (n = 436) using tumor sample data from the TCGA Pan-Cancer Atlas and developed an...
Women who develop breast cancer are tested immediately to see if they are ’Estrogen positive’ (ER+). That oestrogen to blame is most usually ’Oestradiol’ (Estradiol), made by the C-16 pathway and aromatase enzymes in your fat stores. Women in America with ovarian cancer are tested routi...
OVCAR-3 and SKOV-3ip expressed moderate-to-high level of integrins ανβ3 or/and ανβ5 (Figure 1B, 1C, 1E, 1F). The data clearly demonstrated that there was a variation of expressions for HSPG and integrins ανβ3 and ανβ5 on different ovarian cancer cell lines. Not ...